



# NGL Fine-Chem Limited

Regd. Office : 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA.  
Tel.: 022-40842222, 26108030 • Email : info@nglfinechem.com • CIN : L24110MH1981PLC025884 • Website : [www.nglfinechem.com](http://www.nglfinechem.com) February 03, 2026

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai 400 001.

**Scrip Code: 524774**

**National Stock Exchange of India****Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No.C/1, G  
Block, Bandra Kurla Complex, Bandra  
East,  
Mumbai 400050.

**Symbol: NGLFINE**

**Sub: Outcome of the Board Meeting Dated February 3, 2026.**

**Ref: Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

We wish to inform you that, the Board of Directors of the Company at their meeting held today i.e. on Tuesday, February 3, 2026 has inter-alia considered and approved the following:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Report of the Statutory Auditors thereon;
2. Appointment of Mr. Shivam Gharat (ICSI M. No. A56704) as Company Secretary and Compliance Officer of the Company with effect from Tuesday, February 3, 2026.

The relevant details as per the requirements of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed.

The meeting of the Board of Directors commenced at 6.00 p.m. and concluded at 7.25 p.m.

You are requested to kindly take the information on record.

Thanking you,

Yours faithfully,  
For NGL Fine-Chem Limited



Shivam Gharat  
Company Secretary & Compliance Officer  
Membership No: A56704



# MANEK & ASSOCIATES

## CHARTERED ACCOUNTANTS

102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

### SHAILESH MANEK

B.Com. (Hons), Grad. C.W.A., F.C.A.  
Cell : +91 93222 26311

Offi. # 2618 5110  
# 3158 5697  
shailesh.manek@gmail.com  
shailesh@camanek.com  
www.camanek.com

### MITTUL B. DALAL

B.Com. F.C.A.  
Cell : +91 80973 74277

Independent Auditor's Review Report on the unaudited quarter ended consolidated financial results And Year To Date Results of **M/S. NGL Fine-Chem Limited** Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Amended)

To the Board of Directors of **M/S. NGL Fine-Chem Limited**,

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/S. NGL Fine-Chem Limited** ("the Parent") and its subsidiary **M/S. Macrotech Polychem Private Limited** (the Parent and its subsidiary together referred to as "the Group", and its share of the net profit/loss) after tax and total comprehensive income/loss of its associates and joint ventures for the quarter and nine months ended **December 31, 2025** and the year to date results for the period from 1<sup>st</sup> April 2025 to 31<sup>st</sup> December , 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements ) Regulation 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of company personnel, applying analytical and other review procedures applied to financial data. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain

# MANEK & ASSOCIATES

assurance that we would become aware of all significant matters that might be identified in an audit and accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of M/S. Macrotech Polychem Private Limited, its wholly owned subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MANEK & ASSOCIATES  
Chartered Accountants  
Firm's Registration No.:126679W

*~BDalal*

**(MITTUL DALAL)**

Partner

Membership Number:172676

UDIN: 26172676EJVXTC2079



MUMBAI

Dated : 03<sup>rd</sup> February, 2026.



# MANEK & ASSOCIATES

## CHARTERED ACCOUNTANTS

102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

### SHAILESH MANEK

B.Com. (Hons), Grad. C.W.A., F.C.A.  
Cell : +91 93222 26311

Offi. # 2618 5110  
# 3158 5697  
shailesh.manek@gmail.com  
shailesh@camanek.com  
www.camanek.com

### MITTUL B. DALAL

B.Com. F.C.A.  
Cell : +91 80973 74277

Independent Auditor's Review Report on Unaudited Quarterly Financial Results And Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (As Amended)

To The Board of Directors of **M/S.NGL Fine-Chem Limited**

1. We have reviewed the accompanying statement of Unaudited Financial results of **M/S.NGL Fine-Chem Limited** ("the Company") for the quarter and nine months ended **December 31, 2025** , and the year to date results for the period from 1<sup>st</sup> April 2025 to 31st December, 2025 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 , as amended ( the " Listing Regulations" ).
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("IND AS 34") " Interim Financial Reporting" prescribed under Section 133 of the Companies Act , 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements ) Regulation 2015. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of company personnel, applying analytical and other review procedures applied to financial data. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit and accordingly, we do not express an audit opinion.

# MANEK & ASSOCIATES

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("IND AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For **MANEK AND ASSOCIATES**  
**Chartered Accountants**  
Firm's Registration No.:**126679W**



*~B Dalal*

**(MITTUL DALAL)**

Partner

Membership Number:**172676**

UDIN: **26172676KRHGIS9527**

MUMBAI

Dated: **03<sup>rd</sup> February, 2026.**

# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle ( East), Mumbai 400 057

CIN: L24110MH1981PLC025884



## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2025

Rupees in lakhs

Part I: Statement of Consolidated and Standalone Unaudited Results for the Quarter and Nine months ended 31st December 2025

	Particulars	Consolidated						Standalone					
		Quarter Ended			Nine month Ended		Year Ended	Quarter Ended			Nine month Ended		Year Ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)	31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
I	Revenue from Operations	12,750.99	12,025.83	8,909.88	35,188.71	27,333.62	36,825.67	12,633.09	11,683.93	8,683.17	34,402.82	26,627.60	35,929.35
II	Other Income	461.15	205.30	(13.19)	1,310.00	1,059.07	863.04	468.85	241.02	15.26	1,333.69	1,157.12	975.84
III	Total Revenue (I+II)	13,212.14	12,231.13	8,896.69	36,498.71	28,392.69	37,688.70	13,101.94	11,924.95	8,698.43	35,736.51	27,784.72	36,905.19
IV	Expenses :												
	a) Cost of Material Consumed	6,270.50	6,189.14	4,793.36	17,991.85	13,509.84	18,241.25	6,398.82	6,355.42	4,982.37	18,156.85	13,583.23	18,379.74
	b) (Increase)/Decrease in stock in trade and work in progress	(319.38)	(462.05)	(440.47)	(1,124.42)	(22.20)	(0.59)	(247.75)	(574.41)	(473.03)	(1,123.03)	40.09	135.66
	c) Employee benefits expenses	1,708.46	1,569.51	1,466.28	4,854.11	4,129.88	5,554.61	1,572.46	1,436.55	1,325.07	4,456.02	3,777.10	5,071.37
	d) Finance Costs	107.47	116.23	60.05	345.89	136.05	233.41	105.60	115.44	60.05	340.68	136.05	230.74
	e) Depreciation and amortisation expenses	518.08	508.50	309.90	1,453.17	913.06	1,245.11	434.96	426.42	229.52	1,206.06	673.76	926.95
	f) Other expenses	2,860.04	3,013.66	2,581.04	8,431.02	7,087.88	9,643.49	2,900.45	3,099.87	2,493.34	8,725.43	7,150.21	9,772.50
	Total Expenses (IV)	11,145.16	10,934.98	8,770.16	31,951.63	25,754.51	34,917.28	11,164.54	10,859.30	8,617.32	31,762.01	25,360.44	34,516.96
V	Profit/(loss) before exceptional items and tax (III-IV)	2,066.99	1,296.15	126.53	4,547.08	2,638.18	2,771.42	1,937.40	1,065.65	81.11	3,974.50	2,424.28	2,388.23
VI	Exceptional Items												
VII	Profit/(loss) Before Tax (V-VI)	2,066.99	1,296.15	126.53	4,547.08	2,638.18	2,771.42	1,937.40	1,065.65	81.11	3,974.50	2,424.28	2,388.23
VIII	Tax Expense												
	a) Current Tax	(468.00)	(400.00)	(115.00)	(998.00)	(615.00)	(650.50)	(430.00)	(339.00)	(115.00)	(840.00)	(560.00)	(560.00)
	b) Prior Years	-	-	2.38	(0.88)	2.38	27.80	-	-	-	(0.88)	-	25.60
	c) Deferred Tax	(29.92)	66.40	113.75	(92.53)	5.27	(36.30)	(33.78)	63.13	112.17	(105.83)	1.00	(40.63)
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	1,569.07	962.55	127.66	3,455.67	2,030.83	2,112.43	1,473.62	789.78	78.28	3,027.79	1,865.28	1,813.20
X	Other Comprehensive Income												
	a. Gain/(Loss) on actuarial valuation of post employment benefits	(5.63)	18.43	8.32	(19.91)	(30.61)	(32.13)	(5.87)	17.50	7.99	(20.59)	(30.77)	(32.48)
	b. Deferred tax on above	1.42	(4.65)	(2.10)	5.01	7.71	8.09	1.48	(4.41)	(2.01)	5.18	7.75	8.17
	c. Other Comprehensive Income (Net of Tax)	(4.22)	13.78	6.22	(14.90)	(22.90)	(24.04)	(4.39)	13.10	5.98	(15.41)	(23.03)	(24.30)
XI	Total Comprehensive Income	1,564.85	976.33	133.88	3,440.77	2,007.93	2,088.39	1,469.23	802.87	84.26	3,012.38	1,842.25	1,788.90
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90
XIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	N.A	N.A	27,652.44	N.A	N.A	N.A	N.A	N.A	27,652.44
XIV	Earnings Per Share (EPS)												
	a) Basic	25.40	15.58	2.07	55.93	32.87	34.19	23.85	12.78	1.27	49.01	30.19	29.35
	b) Diluted	25.40	15.58	2.07	55.93	32.87	34.19	23.85	12.78	1.27	49.01	30.19	29.35

Notes:

- 1 The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Tuesday, 3rd February, 2026. These results are subjected to Limited Review by the Statutory Auditors of the Company.
- 2 The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- 3 The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polycem Private Limited.
- 4 On November 21, 2025, the Government of India notified four Labour Codes, effective immediately, replacing the existing 29 labour laws. In accordance with Ind AS 19 – Employee benefits, changes to employee benefit plans arising from legislative amendments are treated as plan amendments, requiring immediate recognition of past service cost in the Statement of Profit and Loss. The Company has assessed and accounted for the incremental impact of these changes with the best information available and guidance provided by the Institute of Chartered Accountants of India, considering that the impact is non-recurring in nature and is driven by regulatory changes, the incremental impact of Rs 37.19 lacs has been disclosed as "Employee Benefit Expenses" in the consolidated statement of profit and loss for the quarter and nine months ended December 31, 2025. The Company continues to monitor the finalization of Central / State rules and clarifications from the Government on other aspects of the Labour Codes and would provide appropriate accounting effect as and when such clarifications are issued/rules are notified.
- 5 Previous period figures have been regrouped/rearranged wherever necessary.





# NGL Fine-Chem Limited

Regd. Office : 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA.

Tel.: 022-40842222, 26108030 • Email : info@nglfinechem.com • CIN : L24110MH1981PLC025884 • Website : www.nglfinechem.com

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular:

Sr No	Particulars	Details
1	Name	<b>Mr. Shivam Gharat</b>
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Shivam Gharat as Company Secretary and Compliance Officer
3	Date of appointment & term of appointment	<b>With effect from February 3, 2026</b>
4	Brief profile (in case of appointment)	Mr. Shivam Gharat is an Associate Member of the Institute of Company Secretaries of India (ICSI) and a Law Graduate, with over eight years of diverse experience in corporate governance, regulatory frameworks, and legal compliance in legal and secretarial activities.
5	Disclosure of relationships between directors (in case of appointment of a director)	<b>Not Applicable</b>

